Loading clinical trials...
Loading clinical trials...
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Conditions
Interventions
Solanezumab
Placebo
Locations
193
United States
Xenoscience
Phoenix, Arizona, United States
Banner Alzheimer's Institute
Phoenix, Arizona, United States
St Josephs Hospital and Medical Center
Phoenix, Arizona, United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
Center for Neurosciences
Tucson, Arizona, United States
Arizona Health Sciences Center
Tucson, Arizona, United States
Start Date
June 1, 2016
Primary Completion Date
May 1, 2017
Completion Date
May 1, 2017
Last Updated
October 10, 2019
NCT06159673
NCT07457138
NCT07033494
NCT07214727
NCT07422857
NCT06584357
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions